-
-
Pharma & Human Health -
Finance -
Finance -
Pharma & Human Health
Editor’s Choice
Editor's Choice
Seres Therapeutics, Nestlé Health Science Announce SER-109 Co-Commercialization License Agreement
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announced today that it has entered into an agreement with Nestlé Health Science to jointly commercialize SER-109, Seres’ investigational oral microbiome therapeutic for recurrent Clostridioides […]
Editor's Choice
Ferring and Rebiotix Present Landmark Phase 3 Data
Ferring Pharmaceuticals and Rebiotix, a Ferring Company, today presented results from the pivotal Phase 3 PUNCH™ CD3 clinical trial, demonstrating superior efficacy and consistent safety of single-dose RBX2660 in reducing recurrence of Clostridioides difficile infection (CDI) […]
Editor's Choice
The surprising evolutionary history of our oral bacteria
Living in and on our bodies are trillions of microbial cells belonging to thousands of bacterial species – our microbiome. These microbes play key roles in human health, but little is known about their evolution. […]
In Case you Missed it:
Pharma & Human Health
Fecal transplant plus fibre improves insulin sensitivity in severely obese
A transplant of healthy gut microbes followed by fibre supplements benefits patients with severe obesity and metabolic syndrome, according to University of Alberta clinical trial findings published today in Nature Medicine. Patients who were given […]
Editor's Choice
Seres Therapeutics, Nestlé Health Science Announce SER-109 Co-Commercialization License Agreement
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announced today that it has entered into an agreement with Nestlé Health Science to jointly commercialize SER-109, Seres’ investigational oral microbiome therapeutic for recurrent Clostridioides […]
Pharma & Human Health
CN Bio’s PhysioMimix™ Adopted by King’s College London to Investigate Chronic Liver Disease
CN Bio, a leading Organ-on-a-chip Company (OOC) that designs and manufactures single and multi-organ microphysiological systems (MPS), today announced that King’s College London, an internationally renowned research university, has adopted the PhysioMimix™ Multi-Organ MPS. Following […]
Pharma & Human Health
BiomeBank submits for market authorisation of microbial therapy
The company behind Australia’s first facility for the manufacturing of microbial therapies has set its sights on global impact, applying to the Therapeutic Goods Administration, Australia’s regulatory authority, for approval of their world-first biologic drug […]
Pharma & Human Health
MaaT Pharma Announces DSMB Approval to Proceed to Cohort 4 out of 5 in Phase 1b CIMON Trial Testing Capsule Formulation of Microbiome Ecosystem Therapy
MaaT Pharma, a clinical-stage biotechnology company focused on developing Microbiome Ecosystem Therapies in oncology, today announced that the Data Safety and Monitoring Board (DSMB) recommended to proceed to the fourth cohort of the dose-finding Phase […]
